Kenjiro Aogi

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi, Cristina Saura, Toshinari Yamashita et al. · New England Journal of Medicine · 2019 · 2K citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani et al. · New England Journal of Medicine · 2017 · 1.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial

Norio Kohno, Kenjiro Aogi, Hironobu Minami et al. · Journal of Clinical Oncology · 2005 · 545 citations

Medicine, Oncology, Pharmacotherapy +17